<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Multiple system atrophy: Clinical features and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Multiple system atrophy: Clinical features and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Multiple system atrophy: Clinical features and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stewart A Factor, DO
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christine Doss Esper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard I Hurtig, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Glenn A Tung, MD, FACR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 17, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple system atrophy (MSA) is rare neurodegenerative disorder that encompasses autonomic, pyramidal, parkinsonian, and cerebellar features. It is one of several neurodegenerative disorders associated with alpha-synuclein aggregation, or synucleinopathies; others include Parkinson disease (PD) and dementia with Lewy bodies (DLB).
        </p>
        <p>
         MSA is important to consider in older adults with progressive autonomic and motor dysfunction. It is referred to as an atypical parkinsonian disorder based on distinct yet overlapping features with PD; other atypical parkinsonian disorders include progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).
        </p>
        <p>
         This topic will review the clinical features and diagnosis of MSA. The epidemiology, pathogenesis, prognosis, and treatment of MSA are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/139535.html" rel="external">
          "Multiple system atrophy: Epidemiology, pathology, and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4891.html" rel="external">
          "Multiple system atrophy: Prognosis and treatment"
         </a>
         .)
        </p>
        <p>
         Other forms of parkinsonism are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14135.html" rel="external">
          "Corticobasal degeneration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14136.html" rel="external">
          "Progressive supranuclear palsy (PSP): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The core clinical features of MSA, which occur in varying combinations, are parkinsonism (bradykinesia plus rigidity and/or tremor), autonomic failure, cerebellar ataxia, and pyramidal signs. The onset of disease can be marked by any characteristic motor or autonomic feature [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4011928198">
         <span class="h2">
          Age of onset
         </span>
         <span class="headingEndMark">
          —
         </span>
         MSA is an adult-onset neurodegenerative disorder. The mean age of onset is 54 to 58 years [
         <a href="#rid2">
          2-4
         </a>
         ], which is younger than that seen in Parkinson disease (PD). Pathologically confirmed cases have been described with an onset as young as 31 years and as old as 78 years [
         <a href="#rid3">
          3
         </a>
         ]. Parkinsonian and cerebellar subtypes have a similar age of onset [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Motor involvement'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2246070941">
         <span class="h2">
          Prodromal symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         In retrospect, patients diagnosed with MSA can at times identify symptoms that began years before the clinical diagnosis was evident. Such early signs and symptoms are seen as a possible window of opportunity for disease-modifying and preventive strategies targeting alpha-synuclein as well as other pathways.
        </p>
        <p>
         Three main features have received the most interest as prodromal symptoms of MSA:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rapid eye movement sleep behavior disorder
         </strong>
         – Among patients with isolated rapid eye movement (REM) sleep behavior disorder (RBD) who are followed longitudinally and eventually develop a neurodegenerative disorder, approximately 5 to 10 percent have MSA [
         <a href="#rid5">
          5,6
         </a>
         ]; most of the remaining 90 percent have either PD or dementia with Lewy bodies (DLB). RBD can emerge up to two decades before clinical motor symptoms are observed. Risk factors for neurodegeneration in patients with RBD are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14894.html" rel="external">
          "Rapid eye movement sleep behavior disorder", section on 'Risk of neurodegenerative disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Isolated autonomic failure
         </strong>
         – Autonomic dysfunction, especially involving the lower urinary tract (eg, urinary incontinence), is a common early symptom of MSA, sometimes preceding all other diagnostic features. In one longitudinal series of patients diagnosed with MSA and queried about early symptoms, initial urinary symptoms were the sole initial manifestation of MSA in 18 percent of patients, occurring at a mean of 2.8 years before motor signs developed [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pure autonomic failure (PAF) or idiopathic orthostatic hypotension, like RBD, is increasingly recognized as a risk factor for future synucleinopathy, with a phenoconversion rate of 12 to 35 percent in various studies with variable follow-up [
         <a href="#rid8">
          8-11
         </a>
         ]. In a series of 275 patients with PAF followed at a tertiary care clinic, 24 percent were eventually diagnosed with a synucleinopathy, most commonly MSA (51 percent) [
         <a href="#rid8">
          8
         </a>
         ]. The median time to conversion to MSA was 5.9 years. Patients eventually diagnosed with MSA tend to be younger and have more severe bladder symptoms as compared with those with PD or DLB.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subtle motor signs
         </strong>
         – Mild parkinsonian signs, especially if symmetric and without tremor, or cerebellar dysfunction that are insufficient to diagnose clinical disease may be present prior to the onset of other disease-defining features. Such features are usually nonspecific, particularly in the absence of other features such as autonomic dysfunction. In patients with subtle or equivocal motor signs and RBD, the presence of hyposmia may point towards a diagnosis of a synucleinopathy, although the severity of hyposmia tends to be lower in MSA than in PD or DLB. In some patients with MSA, the sense of smell may be normal.
        </p>
        <p>
        </p>
        <p>
         In some cases, it may be possible for patients to participate in clinical trials based on isolated symptoms that do not fulfill criteria for clinical disease but that may indicate increased risk for future phenoconversion to MSA or other synucleinopathies. One resource for patients is the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.naps-rbd.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F9hlSSl%2BM1HyYgleLtxjqx%2FlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=4890" target="_blank">
          North American Prodromal Synucleinopathy (NAPS) Consortium
         </a>
         . Research criteria for possible prodromal MSA have been proposed [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Possible prodromal MSA (research only)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Motor involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The motor manifestations of MSA are classified clinically into two separate but overlapping subtypes [
         <a href="#rid13">
          13-15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MSA with predominant parkinsonism (MSA-P)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MSA with predominant cerebellar ataxia (MSA-C)
        </p>
        <p>
        </p>
        <p>
         In most studies from Europe and North America, cases of MSA-P outnumber MSA-C by between two and four to one [
         <a href="#rid2">
          2,16
         </a>
         ]. This contrasts with studies from Japan, which report MSA-C as more common than MSA-P [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         The predominant motor feature can change over time with disease progression [
         <a href="#rid18">
          18
         </a>
         ]. Thus, the designation of MSA-P or MSA-C refers to the predominant motor problem at the time the patient is evaluated.
        </p>
        <p class="headingAnchor" id="H3698713346">
         <span class="h3">
          Parkinsonism (MSA-P)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parkinsonism in MSA-P is characterized by akinesia/bradykinesia, rigidity, postural instability, and/or an irregular jerky postural and action tremor. Up to two-thirds of patients with MSA have this jerky postural tremor involving the arms, which has also been referred to as minipolymyoclonus [
         <a href="#rid19">
          19
         </a>
         ]. Up to one-third of patients with MSA-P also have a mild rest tremor [
         <a href="#rid20">
          20,21
         </a>
         ]. Other warning signs that herald parkinsonism in MSA include postural instability and falls (usually within three years of motor onset), pyramidal signs including extensor plantar responses, and rapid progression regardless of dopaminergic treatment [
         <a href="#rid14">
          14,17
         </a>
         ].
        </p>
        <p>
         Additional movement disorders associated with MSA-P may include stimulus-sensitive cortical myoclonus, hemiballism and chorea, and dystonia unrelated to dopaminergic therapy [
         <a href="#rid22">
          22-24
         </a>
         ]. Specific types of dystonia include orofacial dystonia or dyskinesia, occasionally resembling "risus sardonicus" (spasm of the facial muscles producing a distorted grinning expression), and Pisa syndrome (subacute axial dystonia with severe lateral flexion of the trunk, head, and neck).
        </p>
        <p class="headingAnchor" id="H2170980542">
         <span class="h3">
          Cerebellar dysfunction (MSA-C)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to MSA-P, the motor features of MSA-C involve predominant cerebellar dysfunction that manifests as gait ataxia, limb ataxia, ataxic dysarthria, and cerebellar disturbances of eye movements [
         <a href="#rid14">
          14
         </a>
         ]. Ocular abnormalities may include gaze-evoked nystagmus, impaired smooth pursuits with saccadic intrusion, and/or ocular dysmetria.
        </p>
        <p class="headingAnchor" id="H1422909149">
         <span class="h3">
          Speech and swallowing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dysphagia is a prominent symptom of both clinical subtypes of MSA [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         The speech pattern of patients with MSA is characteristic. In addition to the hypophonic monotony often seen in PD, patients with MSA-P also have an increase in pitch and a quivering, strained element to their speech [
         <a href="#rid14">
          14
         </a>
         ]. By contrast, patients with MSA-C have a more typical cerebellar scanning dysarthria.
        </p>
        <p class="headingAnchor" id="H3503678560">
         <span class="h3">
          Postural abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Camptocormia (severe anterior flexion of the spine)  (
         <a class="graphic graphic_figure graphicRef109736" href="/z/d/graphic/109736.html" rel="external">
          figure 1
         </a>
         ) and disproportionate antecollis  (
         <a class="graphic graphic_figure graphicRef109737" href="/z/d/graphic/109737.html" rel="external">
          figure 2
         </a>
         ) are common abnormalities of posture in MSA [
         <a href="#rid14">
          14,26
         </a>
         ]. The anterocollis, in particular, is characteristic of MSA, although it can occur in other forms of degenerative parkinsonism [
         <a href="#rid27">
          27-29
         </a>
         ].
        </p>
        <p>
         These postural abnormalities may be the result of axial dystonia, myopathy, or perhaps both [
         <a href="#rid30">
          30-32
         </a>
         ]. Some have hypothesized that dystonia is the initial feature and that myopathy appears later due to muscle damage. There are no longitudinal data to support this possibility, however.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Dysautonomia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dysautonomia is a feature of both parkinsonian and cerebellar MSA presentations [
         <a href="#rid14">
          14
         </a>
         ]. Among patients in a large European MSA registry, symptomatic dysautonomia was present in almost all patients, with high rates of urinary dysfunction (83 percent) and symptomatic orthostatic hypotension (75 percent) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urinary dysfunction
         </strong>
         – The most frequently reported urinary symptoms are voiding difficulty (80 percent), nocturia (74 percent), urgency (63 percent), incontinence (63 percent), diurnal frequency (45 percent), nocturnal enuresis (19 percent), and urinary retention (8 percent) [
         <a href="#rid33">
          33
         </a>
         ]. Although these features are also seen in PD, they generally begin earlier and are more profound in MSA [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Urodynamic studies in patients with MSA commonly show impaired detrusor contractility and detrusor-sphincter dyssynergia. In a study of 52 patients with MSA who had undergone urodynamic analysis, detrusor underactivity with dysuria was observed within four years of disease onset in 58 percent of patients and thereafter in 76 percent [
         <a href="#rid35">
          35
         </a>
         ]. Other common findings in MSA include bladder neck incompetence and external sphincter denervation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Postvoid residual (PVR) volumes are often measurable in patients with MSA, indicating some degree of impaired detrusor function, if not frank urinary retention. In longitudinal studies, PVR increases over time in patients with MSA. A significantly elevated PVR (eg, &gt;100 mL) distinguishes patients with MSA from those with PD with high specificity but is not useful in the distinction between MSA and progressive supranuclear palsy (PSP) [
         <a href="#rid12">
          12
         </a>
         ]. Approximately 14 percent of patients with MSA require self-catheterization by five years [
         <a href="#rid36">
          36
         </a>
         ]. A smaller subgroup of patients with probable MSA have urinary retention requiring catheterization at the time of diagnosis [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Erectile dysfunction
         </strong>
         – Nearly all males with MSA have erectile dysfunction, which is usually an early symptom [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Orthostatic hypotension
         </strong>
         – In the natural history of MSA, neurogenic orthostatic hypotension usually emerges after urogenital symptoms appear. In a cross-sectional study of 100 patients with MSA, symptomatic orthostatic hypotension was present in 68 percent and was severe in 15 percent [
         <a href="#rid15">
          15
         </a>
         ]. For the purposes of the diagnostic criteria for MSA, orthostatic hypotension is defined as a drop of 20 mmHg or more in systolic blood pressure within 10 minutes of standing. Patients will usually but not always have a corresponding drop in diastolic blood pressure of ≥10 mmHg and a lack of compensatory increase in heart rate (in the absence of beta blockers or other medications that may blunt the heart rate response). (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anhydrosis
         </strong>
         – Up to 80 percent of patients have decreased sweating, including nearly half with anhydrosis [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Constipation
         </strong>
         – Constipation is a common symptom of autonomic dysfunction in patients with MSA. Electromyography of the external anal sphincter may show chronic reinnervation with markedly prolonged motor units [
         <a href="#rid39">
          39-41
         </a>
         ]. Such changes are supportive of MSA but not specific; similar changes can be seen in PD as well as with cauda equina injury and following pelvic or obstetric surgery or injury [
         <a href="#rid12">
          12,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1172381573">
         <span class="h2">
          Nonmotor features
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Sleep and breathing disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sleep and breathing abnormalities are common in MSA. A retrospective study of 45 patients with MSA who underwent video polysomnography revealed sleep-related breathing disorders in 62 percent, including stridor (38 percent), obstructive sleep apnea (31 percent), central sleep apnea (9 percent), and ataxic breathing (2 percent) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         At least two-thirds of patients have RBD [
         <a href="#rid44">
          44,45
         </a>
         ]. RBD is characterized by loss of the usual muscle atony during REM sleep, leading patients to act out their dreams. The content of the dreams is often vivid, violent, or frightening. Patients may talk or shout during sleep and may strike out at their bed partner. The emergence of RBD may precede the motor manifestations of MSA by several years or even decades in some cases [
         <a href="#rid5">
          5,46
         </a>
         ]. Patients with early RBD may be more likely to have an autonomic onset of MSA and less likely to manifest parkinsonism [
         <a href="#rid45">
          45
         </a>
         ]. RBD tends to decrease in severity as the disease progresses [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14894.html" rel="external">
          "Rapid eye movement sleep behavior disorder"
         </a>
         .)
        </p>
        <p>
         Nocturnal or diurnal laryngeal stridor occurs in approximately 15 to 40 percent of patients with MSA [
         <a href="#rid47">
          47
         </a>
         ]. It is a fairly specific feature of MSA, which is uncommon in PD and other neurodegenerative disorders [
         <a href="#rid16">
          16
         </a>
         ]. Stridor is caused by laryngospasm with impaired vocal cord abduction and/or paradoxical adduction. The sound is high-pitched and occurs with inspiration as air vibrates the narrowed vocal folds. Families may mistake it for loud snoring.
        </p>
        <p>
         Stridor usually begins during sleep but can be present during the daytime in advanced cases. Early emergence of stridor has been associated with shorter survival in patients with MSA [
         <a href="#rid48">
          48
         </a>
         ], and it may be a risk factor for sudden death in sleep. Patients with stridor should be referred to otolaryngology and for evaluation. (See
         <a class="medical medical_review" href="/z/d/html/4891.html" rel="external">
          "Multiple system atrophy: Prognosis and treatment", section on 'Stridor'
         </a>
         .)
        </p>
        <p>
         Both excessive daytime sleepiness and restless legs syndrome are present in nearly 30 percent of patients with MSA, rates that are similar to or greater than those seen in PD [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29758549">
         <span class="h3">
          Cognitive function
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cognitive function in MSA tends to be relatively preserved compared with PD and other atypical parkinsonian disorders, possibly reflecting a lesser degree of cortical involvement in MSA [
         <a href="#rid50">
          50
         </a>
         ] and the younger age of onset. Nevertheless, although cognitive impairment in MSA is uncommon, it does occur, and its presence does not exclude MSA as a clinical diagnosis in patients who have classic symptoms and signs of the disorder.
        </p>
        <p>
         A multicenter European study evaluated a prospective cohort of 372 patients with a clinical diagnosis of MSA and found cognitive impairment in approximately 20 percent, predominantly involving diminished verbal fluency, perseveration, and executive dysfunction, as seen in PD and PSP [
         <a href="#rid51">
          51
         </a>
         ]. One limitation of this report is that few patients had pathologic confirmation of the clinical diagnosis, and among those who did, the clinical diagnosis of MSA was proven wrong in 35 percent of those with cognitive impairment compared with 5 percent of those without cognitive impairment. Thus, this study probably overestimated the rate of cognitive impairment in MSA.
        </p>
        <p>
         Patients with MSA can develop emotional incontinence (also called pseudobulbar affect), characterized by crying inappropriately without sadness or laughing inappropriately without mirth. This manifestation is also seen, perhaps more commonly, in PSP. (See
         <a class="medical medical_review" href="/z/d/html/14136.html" rel="external">
          "Progressive supranuclear palsy (PSP): Clinical features and diagnosis", section on 'Cognitive and behavioral abnormalities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29758569">
         <span class="h3">
          Other features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with MSA may have an associated Raynaud phenomenon (an exaggerated vascular response to cold temperature or emotional stress) and/or cold, dusky extremities that blanch on pressure with poor circulatory return. These symptoms may be provoked by ergot drugs. (See
         <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">
          "Clinical manifestations and diagnosis of Raynaud phenomenon"
         </a>
         .)
        </p>
        <p>
         MSA is associated with high rates of anxiety, depression, and fatigue [
         <a href="#rid52">
          52,53
         </a>
         ]. In one study of 286 patients with MSA, probable depression and probable anxiety were present in 43 and 37 percent, respectively [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Olfactory dysfunction is generally mild in MSA [
         <a href="#rid54">
          54
         </a>
         ]; a small case-control study found that olfactory dysfunction in MSA is less severe than that seen in PD [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2281366322">
         <span class="h2">
          Exclusionary features
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of "red flag" or exclusionary features can help to distinguish MSA from other parkinsonian disorders. These features occasionally occur in patients with pathologically confirmed MSA, particularly late in the disease, and the presence of a single feature does not exclude the diagnosis. However, the presence of any of these findings at the time of presentation should signal that an alternative diagnosis may be more likely.
        </p>
        <p>
         For the purposes of the formal diagnostic criteria for MSA, exclusionary features include the following [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Substantial and persistent beneficial response to dopaminergic medications (see
         <a class="local">
          'Levodopa response assessment'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anosmia (severe loss of olfaction) on olfactory testing (not explained by other common causes such as allergic rhinitis, smoking, structural nasal lesions, or nasal surgery)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal cardiac sympathetic imaging (
         <sup>
          123
         </sup>
         I-metaiodobenzylguanidine [MIBG, iobenguane]-scintigraphy)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluctuating cognition with early decline in visuoperceptual abilities
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent visual hallucinations (not secondary to medications) within three years of disease onset
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dementia  (
         <a class="graphic graphic_table graphicRef91276" href="/z/d/graphic/91276.html" rel="external">
          table 1
         </a>
         ) within three years of disease onset
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Downgaze supranuclear palsy (more suggestive of PSP)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain magnetic resonance imaging (MRI) findings suggestive of an alternative diagnosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An alternative condition known to produce autonomic failure, ataxia, or parkinsonism and plausibly connected to the patient's symptoms
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Common MRI findings in patients with MSA include  (
         <a class="graphic graphic_diagnosticimage graphicRef140968" href="/z/d/graphic/140968.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef140969" href="/z/d/graphic/140969.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid18">
          18,56-58
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrophy of the putamen, pons, middle cerebellar peduncles, and cerebellum
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T2 hypointensity of the posterior putamen (also described as a slit-like void), T2 hyperintensity in the lateral putaminal rim ("putaminal rim sign"), and T2 hyperintensities of the middle cerebellar peduncles
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Hot cross bun" sign, referring to hyperintense T2 signal in the shape of a cross within the pons that arises from degeneration of transverse pontocerebellar fibers
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased diffusivity (high apparent diffuse coefficient [ADC] values) in the putamen and middle cerebellar peduncles
        </p>
        <p>
        </p>
        <p>
         These changes are supportive of the diagnosis of MSA rather than PD. However, they are not necessarily present in all patients with MSA, particularly early in the disease. In addition, these signs are not specific for differentiating MSA from other atypical parkinsonian disorders, including PSP [
         <a href="#rid56">
          56
         </a>
         ]. Even the "hot cross bun" sign is not specific and can be seen in patients with other causes of parkinsonism and ataxia [
         <a href="#rid58">
          58-60
         </a>
         ].
        </p>
        <p>
         Compared with visual inspection of individual patient MRIs, quantitative comparisons of atrophy and diffusivity patterns among groups of patients with MSA versus other parkinsonian disorders reveal differences that may eventually prove useful in the clinic. In one systematic review, putaminal diffusivity had high sensitivity and specificity (90 and 93 percent) for distinguishing between patients with MSA-P and PD [
         <a href="#rid61">
          61
         </a>
         ]. Preliminary data suggest that this technique can also be used to monitor disease progression in MSA [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Positron emission tomography using 18-F fluorodeoxyglucose (FDG-PET) in patients with MSA may reveal regional glucose hypometabolism in the striatum, brainstem, and cerebellum, similar to atrophy patterns visualized on structural MRI. However, similar to MRI, the sensitivity and specificity of these findings for differentiating MSA from PD remain uncertain [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Striatal dopamine transporter imaging using single-photon emission computed tomography (SPECT; eg,
         <sup>
          123
         </sup>
         I-FP-CIT SPECT scan or DaTscan) is typically abnormal in patients with MSA, as it is in patients with PD and other parkinsonian disorders. An abnormal result may be most useful clinically in patients with predominant ataxia, to help distinguish MSA from other causes of adult-onset ataxia. (See
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease", section on 'DaTscan'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H352851228">
         <span class="h2">
          Other biomarkers
         </span>
         <span class="headingEndMark">
          —
         </span>
         No positive biomarkers of MSA have yet emerged whose presence points specifically to a clinicopathologic diagnosis of MSA. In some cases, however, the absence of a finding (or a normal result) helps to point towards an alternative diagnosis.
        </p>
        <p>
         One example is
         <sup>
          123
         </sup>
         I-MIBG imaging of the heart, which demonstrates postganglionic abnormalities in patients with PD but not those with MSA [
         <a href="#rid63">
          63,64
         </a>
         ]. This cardiac imaging technique shows promise for differentiating the two diseases, but its clinical utility has yet to be established. Reduced sympathetic innervation can occur due to nondegenerative etiologies as well, including medication effects, structural heart disease, and diabetic small fiber neuropathy.
        </p>
        <p>
         Another potential approach is the use of skin biopsy. Peripheral deposition of alpha-synuclein has been identified within cutaneous autonomic nerve fibers seen on skin biopsy tissue, particularly in synucleinopathies including PD, RBD, DLB, PAF, and MSA. This has led to a growing interest in the use of this technique as a minimally invasive diagnostic biomarker. Although skin biopsy test kits are available commercially for clinical use, more longitudinal studies are needed to understand their usefulness in diagnosis. Several studies indicate potential utility in distinguishing between PD and MSA. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study included neurologic examination, autonomic testing, and skin biopsies in 31 patients with probable MSA per diagnostic criteria, 54 patients with definite PD per the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria, and 24 matched controls [
         <a href="#rid65">
          65
         </a>
         ]. Patients with PD had reduced nerve fiber densities compared with patients with MSA and controls. All 31 patients with MSA and 51 of 54 patients with PD had evidence of phosphorylated alpha-synuclein (P-syn) in at least one skin biopsy. No P-syn was detected in controls. Patients with MSA had greater P-syn deposition and more widespread peripheral distribution than patients with PD. PD followed a proximal-distal gradient, while MSA appeared more evenly distributed. A variety of individual metrics and cutoffs were able to distinguish PD from MSA with high sensitivity and specificity on receiver operating characteristic (ROC) curve analyses. Validation on external cohorts has not yet been reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study compared P-syn staining in skin biopsies of 25 patients with MSA-P and 25 patients with PD with orthostatic hypotension (PD-OH) [
         <a href="#rid66">
          66
         </a>
         ]. Biopsies from patients with MSA-P mainly showed somatic (epidermal) fiber involvement with relatively preserved autonomic innervation; by contrast, PD-OH biopsies displayed prevalent abnormal P-syn deposits and denervation in autonomic postganglionic nerves. This study did not show the similar proximal-distal gradients like the other study, and density of synuclein staining was greater in the PD group.
        </p>
        <p>
        </p>
        <p>
         In a separate technique, seed amplification assays (SAAs; eg, real-time quaking-induced conversion [RT-QuIC] and protein misfolding cyclic amplification [PMCA]) can detect and quantify alpha-synuclein in a variety of tissues, including blood, cerebrospinal fluid, olfactory mucosa, and skin biopsy homogenates. Alpha-synuclein SAAs are able to distinguish patients with synucleinopathies from control subjects and those with non-synuclein neurodegenerative diseases with relatively high sensitivity and specificity but do not perform as well in distinguishing between PD and MSA [
         <a href="#rid67">
          67-69
         </a>
         ].
        </p>
        <p>
         Other potential biomarkers are being studied but are not widely available or do not have sufficient specificity to be useful clinically [
         <a href="#rid12">
          12
         </a>
         ]. These include alpha-synuclein oligomers in cerebrospinal fluid (CSF), which may be elevated in any of the synucleinopathies; neurofilament light chain levels in plasma and CSF, which may be elevated in patients with MSA but low in patients with PD and DLB; and supine norepinephrine levels in association with orthostatic hypotension, which are relatively preserved (&gt;100 picograms/mL) in patients with MSA but lower in those with PD.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         MSA should be suspected in patients with adult-onset, progressive parkinsonism and/or cerebellar dysfunction associated with early or severe dysautonomia. The diagnosis of MSA is based upon the clinical features. No laboratory or imaging studies are diagnostic, particularly since findings are often normal or equivocal in early disease.
        </p>
        <p class="headingAnchor" id="H1447049023">
         <span class="h2">
          History and neurologic examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         History and neurologic examination are central to the diagnosis of MSA, both to confirm key clinical features of the disease and to rule out alternative and competing disorders.
        </p>
        <p>
         Key elements of the history include the nature and timing of first symptoms, ideally with collateral information from family and friends, speed of progression, and impact on function. MSA tends to begin at an earlier age and progress more rapidly than Parkinson disease (PD), with early postural instability and falls and relative sparing of cognition and memory. Patients and bed partners should be asked about dream enactment suggestive of rapid eye movement (REM) sleep behavior disorder (RBD), which they may not volunteer on their own. RBD is common in prodromal and established synucleinopathies and can be a key clue in the differentiation between MSA and nonsynuclein disorders such as progressive supranuclear palsy (PSP) or other causes of ataxia. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
         The urologic history includes questions about storage symptoms (urinary urgency, daytime frequency, nocturia, urge incontinence), voiding symptoms (hesitancy, intermittent urinary stream or poor flow, sensation of incomplete bladder emptying), and erectile dysfunction in males. Measurement of the postvoid residual (PVR) volume by ultrasound is useful if available in the clinic. Depending on the comfort level of the neurologist and primary care clinician, patients may need to be referred to urology to evaluate for prostate enlargement or pelvic floor pathology as competing causes of lower urinary tract symptoms. (See
         <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">
          "Female urinary incontinence: Evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6879.html" rel="external">
          "Lower urinary tract symptoms in males", section on 'Lifestyle and behavioral therapy for all patients'
         </a>
         .)
        </p>
        <p>
         Patients should be asked about signs and symptoms of orthostatic hypotension, including episodes of syncope and falls related to lightheadedness, visual blurring, cognitive slowing, leg buckling, and neck pain and headache localized in the suboccipital, posterior cervical, and shoulder region ("coat-hanger sign"). The medication list should be reviewed for causal or contributing medications  (
         <a class="graphic graphic_table graphicRef130809" href="/z/d/graphic/130809.html" rel="external">
          table 2
         </a>
         ). The diagnostic evaluation for orthostatic hypotension is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5103.html" rel="external">
          "Mechanisms, causes, and evaluation of orthostatic hypotension", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Levodopa response assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Levodopa responsiveness should be tested in all patients with parkinsonism, not only to help distinguish MSA from PD but also for the chance of symptomatic benefit. For a diagnostic trial of levodopa to be valid in this setting, it is essential that the daily dose be high enough (900 to 1000 mg) to avoid a false-negative result. Furthermore, some patients who later in the clinical course of progressive parkinsonism meet diagnostic criteria for MSA will show an early positive response to levodopa, thereby producing a falsely positive diagnosis of PD.
        </p>
        <p>
         In the early stages, MSA with predominant parkinsonism (MSA-P) may be difficult to distinguish from PD [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An excellent and sustained response to dopaminergic therapy is an important supportive feature for establishing the diagnosis of PD. (See
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease", section on 'Response to dopaminergic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By contrast, a poor or unsustained response to levodopa therapy is generally observed in patients with MSA [
         <a href="#rid35">
          35,70,71
         </a>
         ]. While open-label and retrospective studies suggest transient benefit from levodopa in 30 to 50 percent of patients with MSA [
         <a href="#rid15">
          15,20,35,70-75
         </a>
         ], levodopa does not provide long-term benefit in MSA, and the loss of responsiveness can occur abruptly. However, treatment must be individualized since some patients will function better on levodopa than without it.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with young-onset disease (before age 40 years) may be more likely to show levodopa responsiveness than patients with later-onset MSA [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Levodopa responsiveness is tested by administering
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         in escalating doses up to 1000 mg of levodopa daily as necessary and tolerated over several months [
         <a href="#rid14">
          14
         </a>
         ]. A positive response requires a clinically significant improvement in motor symptoms, defined objectively as a 20 to 30 percent improvement in the motor component of the Unified Parkinson Disease Rating Scale (UPDRS) for at least a month [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         As in PD, levodopa treatment may trigger or exacerbate orthostatic hypotension in patients with MSA [
         <a href="#rid14">
          14
         </a>
         ]. Levodopa use can also result in motor fluctuations and dyskinesia. As an example, a case series that included 18 patients with MSA-P reported that levodopa-induced dyskinesia developed in 12 (67 percent) [
         <a href="#rid77">
          77
         </a>
         ]. Levodopa-induced dyskinesia in patients with MSA is not uncommonly restricted to the neck or face, and often consists of sustained dystonic spasms. Levodopa-induced unilateral facial dystonic spasms are particularly suggestive of MSA [
         <a href="#rid78">
          78
         </a>
         ]. Some patients with MSA may develop generalized dyskinesia as seen in PD.
        </p>
        <p class="headingAnchor" id="H222485202">
         <span class="h2">
          Other testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Structural MRI should be performed in all patients to exclude findings suggestive of an alternative diagnosis [
         <a href="#rid12">
          12
         </a>
         ]. The basal ganglia, brainstem, and cerebellum should also be inspected for atrophy and T2 signal changes supportive of MSA. (See
         <a class="local">
          'Neuroimaging'
         </a>
         above.)
        </p>
        <p>
         No other testing is required in most patients. Urodynamic studies and tilt table testing can be useful in selected patients to clarify the etiology of symptoms when the history is unclear or uninformative. In-laboratory polysomnography is useful in some patients to evaluate for RBD and sleep-related breathing disorders. (See
         <a class="local">
          'Sleep and breathing disorders'
         </a>
         above.)
        </p>
        <p>
         Exploratory biomarkers are primarily used for research related to possible prodromal MSA. (See
         <a class="local">
          'Other biomarkers'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnostic criteria for MSA were revised substantially in 2022 to include supportive brain MRI findings as well as proposed research criteria for possible prodromal MSA [
         <a href="#rid12">
          12,13,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H292029529">
         <span class="h3">
          Clinically established MSA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of clinically established MSA during life requires all of the following  (
         <a class="graphic graphic_table graphicRef140972" href="/z/d/graphic/140972.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A sporadic, progressive, adult-onset (&gt;30 years old) disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autonomic dysfunction defined as (at least one is required):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unexplained voiding difficulties with PVR volume ≥100 mL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unexplained urinary urge incontinence
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neurogenic orthostatic hypotension defined by a blood pressure reduction within three minutes of standing by ≥20 mmHg systolic or ≥10 mmHg diastolic
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least one of:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor, or postural instability)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebellar syndrome (at least two of gait ataxia, limb ataxia, cerebellar dysarthria, or oculomotor dysfunction)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least two supportive motor or nonmotor clinical features:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rapid progression within three years of motor onset
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Moderate to severe postural instability within three years of motor onset
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Craniocervical dystonia induced or exacerbated by levodopa in the absence of limb dyskinesia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe speech impairment within three years of motor onset
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe dysphagia within three years of motor onset
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unexplained Babinski sign
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Jerky myoclonic postural or kinetic tremor (minipolymyoclonus)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Postural deformities
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stridor
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inspiratory sighs
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cold discolored hands and feet
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Erectile dysfunction (below age of 60 years for clinically probable)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pathologic laughter or crying
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least one brain MRI marker (each affected brain region as evidenced by atrophy or increased diffusivity counts as one MRI marker):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For MSA with predominant parkinsonism (MSA-P) – Atrophy of putamen (and signal decrease on iron-sensitive sequences), middle cerebellar peduncle, pons, and/or cerebellum; "hot cross bun" sign; and/or increased diffusivity of putamen and/or middle cerebellar peduncle
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For MSA with predominant cerebellar ataxia (MSA-C) – Atrophy of putamen (and signal decrease on iron-sensitive sequences), infratentorial structures (pons and middle cerebellar peduncle); "hot cross bun" sign; and/or increased diffusivity of putamen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of exclusionary features (see
         <a class="local">
          'Exclusionary features'
         </a>
         above)
        </p>
        <p>
        </p>
        <p>
         In a study from the Queen Square Brain Bank using post-mortem neuropathologic diagnosis as a gold standard, these criteria had high specificity (100 percent) but low sensitivity (20 percent) when applied early in the disease course (within three years of symptom onset) [
         <a href="#rid79">
          79
         </a>
         ]. Sensitivity improved to 51 percent when applied in the final stages of disease. As expected, sensitivity was higher for clinically probable MSA (62 and 95 percent for early and late time points, respectively), while specificity remained high (&gt;90 percent). Other autopsy validation studies have shown similar results [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H216485417">
         <span class="h3">
          Clinically probable MSA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of clinically probable MSA requires all of the following  (
         <a class="graphic graphic_table graphicRef140972" href="/z/d/graphic/140972.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A sporadic, progressive, adult-onset (&gt;30 years old) disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least two of:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Autonomic dysfunction defined as (at least one is required):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Unexplained voiding difficulties with PVR of any volume
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Unexplained urinary urge incontinence
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Neurogenic orthostatic hypotension defined as a blood pressure reduction within 10 minutes of standing by ≥20 mmHg systolic or ≥10 mmHg diastolic
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Parkinsonism (bradykinesia plus rigidity or tremor, irrespective of response to levodopa)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebellar syndrome (at least one of gait ataxia, limb ataxia, cerebellar dysarthria, or oculomotor dysfunction)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least one supportive motor or nonmotor clinical feature (same list as above) (see
         <a class="local">
          'Clinically established MSA'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of exclusionary features (see
         <a class="local">
          'Exclusionary features'
         </a>
         above)
        </p>
        <p>
        </p>
        <p>
         As defined, the core clinical features of clinically probable MSA are more sensitive and usually manifest earlier compared with the core features of clinically established MSA [
         <a href="#rid12">
          12,79
         </a>
         ]. Therefore, many patients who initially meet criteria for clinically probable MSA will go on to meet criteria for established MSA over time.
        </p>
        <p class="headingAnchor" id="H1657260995">
         <span class="h3">
          Possible prodromal MSA (research only)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Research criteria for possible prodromal MSA were added to the Movement Disorder Society (MDS) diagnostic criteria in 2022 but are not intended for clinical use. According to the criteria, possible prodromal MSA exists when all of the following are met [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A sporadic, progressive, adult-onset (&gt;30 years old) disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least one clinical nonmotor feature:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RBD (polysomnography proven)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neurogenic orthostatic hypotension (≥20 mmHg systolic blood pressure drop) within 10 minutes of standing or head-up tilt
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urogenital failure (erectile dysfunction in males below age 60 years combined with at least one of unexplained voiding difficulties with PVR &gt;100 mL and unexplained urinary urge incontinence)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least one clinical motor feature:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Subtle parkinsonian signs
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Subtle cerebellar signs
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of all of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unexplained anosmia on olfactory testing and/or abnormal cardiac sympathetic imaging
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fluctuating cognition with pronounced variation in attention and alertness and early decline in visuoperceptual abilities
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recurrent visual hallucinations not induced by drugs within three years of disease onset
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dementia within three years of disease onset
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Downgaze supranuclear palsy or slowing of vertical saccades
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Brain MRI findings suggestive of an alternative diagnosis (eg, PSP, multiple sclerosis, vascular parkinsonism, symptomatic cerebellar disease)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alternative condition known to produce autonomic failure, ataxia, or parkinsonism and plausibly connected to patient’s symptoms
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H116176">
         <span class="h2">
          Role of genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not perform genetic testing routinely in patients with probable MSA but consider it when atypical features suggest the possibility of spinocerebellar ataxia (SCA), such as younger onset, slower progression, decreased instead of increased reflexes, or positive family history. Such cases are rare, however.
        </p>
        <p>
         In a retrospective report from Korea, 302 patients with a clinical diagnosis of probable or possible MSA (by older diagnostic criteria) had genetic testing for some of the more common types of SCA [
         <a href="#rid81">
          81
         </a>
         ]. Those with MSA-C were more likely to be tested. Most patients, irrespective of clinical phenotype, had cerebellar atrophy on MRI. Mutations in SCA genes  (
         <a class="graphic graphic_table graphicRef74269" href="/z/d/graphic/74269.html" rel="external">
          table 4
         </a>
         ) were found in 22 patients (7 percent) with trinucleotide expansion repeats in genes responsible for SCA17 (n = 13), SCA2 (n = 3), SCA6 (n = 3), SCA1 (n = 1), SCA3 (n = 1), and dentatorubral pallidoluysian atrophy (n = 1). Seventeen of the 22 patients had cerebellar findings on neurologic examination (ie, suggesting MSA-C or mixed subtype), whereas only five were diagnosed clinically with MSA-P. Among the 22 SCA cases, the mean age at onset was 59 years, similar to the patients without SCA mutations, and only three patients had a family history of cerebellar ataxia. (See
         <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">
          "Autosomal dominant spinocerebellar ataxias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is important to distinguish MSA from Parkinson disease (PD) because of differences in prognosis and treatment. It is also important to differentiate it from other atypical parkinsonian disorders, mainly progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). In clinicopathologic studies, the accuracy of a clinical diagnosis of MSA ranges from 60 to 80 percent when compared with autopsy findings [
         <a href="#rid82">
          82-84
         </a>
         ]. The distinction between MSA with predominant parkinsonism (MSA-P) and PSP can be particularly difficult during life [
         <a href="#rid85">
          85
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
         Among various clinical features, we find the following clues most meaningful in the clinic when considering the diagnosis of MSA and its common mimics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Levodopa response assessment
         </strong>
         – The primary feature that clinically distinguishes MSA-P from PD in most cases is the lack of a sustained and dramatic reduction in clinical symptoms and signs with levodopa therapy (see
         <a class="local">
          'Levodopa response assessment'
         </a>
         above). Additional clues include the presence of other characteristic features of MSA, such as autonomic failure, the jerky postural tremor, ataxia (in MSA with predominant cerebellar ataxia [MSA-C]), and pyramidal tract signs [
         <a href="#rid76">
          76,84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vertical eye movements
         </strong>
         – The presence of vertical eye movement abnormalities and the absence of orthostatic hypotension suggest PSP. (See
         <a class="medical medical_review" href="/z/d/html/14136.html" rel="external">
          "Progressive supranuclear palsy (PSP): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limb apraxia
         </strong>
         – Apraxia is a relatively unusual sign, and its presence suggests CBD rather than MSA. (See
         <a class="medical medical_review" href="/z/d/html/14135.html" rel="external">
          "Corticobasal degeneration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         However, there is overlap among these conditions. MSA may sometimes present with the phenotype of PSP, including vertical eye movement abnormalities [
         <a href="#rid84">
          84,85
         </a>
         ]. In addition, patients with a pure akinetic-rigid syndrome may be impossible to diagnose because PD can present in this manner.
        </p>
        <p>
         Among patients with idiopathic adult-onset cerebellar ataxia, 21 to 33 percent will meet clinical criteria for MSA-C [
         <a href="#rid16">
          16,86,87
         </a>
         ]. Disorders that may present with predominant cerebellar dysfunction and other features overlapping with MSA-C include [
         <a href="#rid81">
          81,88
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Various types of spinocerebellar ataxia (SCA), including SCA2, SCA3, SCA6, and SCA17 (see
         <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">
          "Autosomal dominant spinocerebellar ataxias"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late-onset Friedreich ataxia (see
         <a class="medical medical_review" href="/z/d/html/6224.html" rel="external">
          "Friedreich ataxia"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The fragile X-associated tremor/ataxia syndrome (see
         <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">
          "Autosomal dominant spinocerebellar ataxias", section on 'Fragile X-associated tremor/ataxia syndrome'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Pure autonomic failure (PAF) should be considered if autonomic symptoms are the predominant feature of the disorder and motor involvement is limited or absent. PAF is associated with slower functional deterioration and a better prognosis than MSA [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5103.html" rel="external">
          "Mechanisms, causes, and evaluation of orthostatic hypotension", section on 'Etiologies'
         </a>
         .)
        </p>
        <p>
         Mitochondrial disorders also affect multiple systems but often include other neurologic features such as myopathy, optic neuropathy or retinopathy, and deafness. Systemic features of mitochondrial disorders may include cardiomyopathy and diabetes. (See
         <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">
          "Mitochondrial myopathies: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Multiple system atrophy (MSA) is a rare, adult-onset neurodegenerative disorder characterized by varying combinations of parkinsonism, autonomic dysfunction, cerebellar ataxia, and pyramidal signs. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Motor involvement
         </strong>
         – Motor manifestations of MSA are classified into subtypes according to whether the predominant feature is parkinsonism (MSA-P) or cerebellar dysfunction (MSA-C) at the time of diagnosis. Patients can have features of both, and the predominance can change over time. (See
         <a class="local">
          'Motor involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Patients with MSA-P have akinesia/bradykinesia, rigidity, postural instability, and/or an irregular jerky postural and action tremor. The motor features of MSA-C involve predominant cerebellar dysfunction that manifests as gait ataxia, limb ataxia, ataxic dysarthria, and cerebellar disturbances of eye movements. (See
         <a class="local">
          'Parkinsonism (MSA-P)'
         </a>
         above and
         <a class="local">
          'Cerebellar dysfunction (MSA-C)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Patients with either subtype commonly have dysphagia and altered speech, which may be hypophonic, high-pitched, or dysarthric and scanning. Postural abnormalities, such as antecollis and camptocormia, can be prominent. (See
         <a class="local">
          'Speech and swallowing'
         </a>
         above and
         <a class="local">
          'Postural abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dysautonomia
         </strong>
         – Symptomatic dysautonomia is present in nearly all patients. Common manifestations include early erectile dysfunction in males, urinary dysfunction (eg, urgency, frequency, nocturia, urge incontinence, impaired bladder emptying), constipation, and neurogenic orthostatic hypotension. (See
         <a class="local">
          'Dysautonomia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nonmotor features
         </strong>
         – A majority of patients have one or more sleep disorders, including nocturnal stridor, sleep apnea, and rapid eye movement (REM) sleep behavior disorder (RBD). Cognition and memory are relatively preserved. (See
         <a class="local">
          'Nonmotor features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neuroimaging
         </strong>
         – Brain MRI in patients with clinically established MSA may show atrophy of the putamen, pons, middle cerebellar peduncles, and cerebellum; increased diffusivity in the putamen; and a "hot cross bun" sign within the pons  (
         <a class="graphic graphic_diagnosticimage graphicRef140968" href="/z/d/graphic/140968.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef140969" href="/z/d/graphic/140969.html" rel="external">
          image 2
         </a>
         ). These features are supportive but not sensitive or specific for the diagnosis. (See
         <a class="local">
          'Neuroimaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – MSA should be suspected in patients with adult-onset, progressive parkinsonism and/or cerebellar dysfunction associated with early or severe dysautonomia. History and neurologic examination are central to the diagnosis of MSA, both to confirm key clinical features of the disease and to rule out alternative and competing causes. (See
         <a class="local">
          'History and neurologic examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Levodopa responsiveness should be tested in all patients with parkinsonism. Lack of sustained response to levodopa can help to distinguish MSA from Parkinson disease (PD), but transient benefit from levodopa is observed in 30 to 50 percent of patients with MSA. (See
         <a class="local">
          'Levodopa response assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – MSA is a clinical diagnosis. Diagnostic criteria for MSA recognize clinically established and clinically probable levels of certainty based on clinical features, brain MRI findings, and absence of exclusionary features  (
         <a class="graphic graphic_table graphicRef140972" href="/z/d/graphic/140972.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – MSA shares overlapping clinical features with PD, other atypical parkinsonian disorders, and adult-onset spinocerebellar ataxias (SCAs). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köllensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25:2604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997; 48:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postuma RB, Iranzo A, Hogl B, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 2015; 77:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019; 142:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakakibara R, Panicker J, Simeoni S, et al. Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. Clin Auton Res 2019; 29:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coon EA, Mandrekar JN, Berini SE, et al. Predicting phenoconversion in pure autonomic failure. Neurology 2020; 95:e889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: Predictors of conversion to clinical CNS involvement. Neurology 2017; 88:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannini G, Calandra-Buonaura G, Asioli GM, et al. The natural history of idiopathic autonomic failure: The IAF-BO cohort study. Neurology 2018; 91:e1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: A United States prospective cohort. Ann Neurol 2017; 81:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord 2022; 37:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenning GK, Ben Shlomo Y, Magalhães M, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117 ( Pt 4):835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinn NP. How to diagnose multiple system atrophy. Mov Disord 2005; 20 Suppl 12:S5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002; 125:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaindlstorfer C, Granata R, Wenning GK. Tremor in Multiple System Atrophy - a review. Tremor Other Hyperkinet Mov (N Y) 2013; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geser F, Seppi K, Stampfer-Kountchev M, et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) 2005; 112:1677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su D, Yang S, Hu W, et al. The Characteristics of Tremor Motion Help Identify Parkinson's Disease and Multiple System Atrophy. Front Neurol 2020; 11:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen R, Ashby P, Lang AE. Stimulus-sensitive myoclonus in akinetic-rigid syndromes. Brain 1992; 115 ( Pt 6):1875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salazar G, Valls-Solé J, Martí MJ, et al. Postural and action myoclonus in patients with parkinsonian type multiple system atrophy. Mov Disord 2000; 15:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steiger MJ, Pires M, Scaravilli F, et al. Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration. Mov Disord 1992; 7:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berciano J. Olivopontocerebellar atrophy. A review of 117 cases. J Neurol Sci 1982; 53:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinn N. Disproportionate antecollis in multiple system atrophy. Lancet 1989; 1:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashihara K, Ohno M, Tomita S. Dropped head syndrome in Parkinson's disease. Mov Disord 2006; 21:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spuler S, Krug H, Klein C, et al. Myopathy causing camptocormia in idiopathic Parkinson's disease: a multidisciplinary approach. Mov Disord 2010; 25:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margraf NG, Wrede A, Rohr A, et al. Camptocormia in idiopathic Parkinson's disease: a focal myopathy of the paravertebral muscles. Mov Disord 2010; 25:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord 2010; 25:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askmark H, Eeg-Olofsson K, Johansson A, et al. Parkinsonism and neck extensor myopathy: a new syndrome or coincidental findings? Arch Neurol 2001; 58:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lava NS, Factor SA. Focal myopathy as a cause of anterocollis in Parkinsonism. Mov Disord 2001; 16:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogawa T, Sakakibara R, Kuno S, et al. Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. Nat Rev Urol 2017; 14:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch F, Pichon B, Bonnet AM, et al. Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia. J Neurol 2010; 257:1986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004; 127:2657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 2006; 21:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panicker JN, Simeoni S, Miki Y, et al. Early presentation of urinary retention in multiple system atrophy: can the disease begin in the sacral spinal cord? J Neurol 2020; 267:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iodice V, Lipp A, Ahlskog JE, et al. Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J Neurol Neurosurg Psychiatry 2012; 83:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy. Mov Disord 2004; 19:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997; 20:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994; 151:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Libelius R, Johansson F. Quantitative electromyography of the external anal sphincter in Parkinson's disease and multiple system atrophy. Muscle Nerve 2000; 23:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rekik S, Martin F, Dodet P, et al. Stridor combined with other sleep breathing disorders in multiple system atrophy: a tailored treatment? Sleep Med 2018; 42:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plazzi G, Corsini R, Provini F, et al. REM sleep behavior disorders in multiple system atrophy. Neurology 1997; 48:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannini G, Mastrangelo V, Provini F, et al. Progression and prognosis in multiple system atrophy presenting with REM behavior disorder. Neurology 2020; 94:e1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claassen DO, Josephs KA, Ahlskog JE, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010; 75:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortelli P, Calandra-Buonaura G, Benarroch EE, et al. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology 2019; 93:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannini G, Calandra-Buonaura G, Mastrolilli F, et al. Early stridor onset and stridor treatment predict survival in 136 patients with MSA. Neurology 2016; 87:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno-López C, Santamaría J, Salamero M, et al. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol 2011; 68:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bak TH, Crawford LM, Hearn VC, et al. Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005; 11:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010; 133:2382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010; 25:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Cao B, Hou Y, et al. Fatigue in Patients With Multiple System Atrophy: A Prospective Cohort Study. Neurology 2022; 98:e73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katzenschlager R, Lees AJ. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 2004; 17:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kikuchi A, Baba T, Hasegawa T, et al. Differentiating Parkinson's disease from multiple system atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. Parkinsonism Relat Disord 2011; 17:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks DJ, Seppi K, Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009; 24:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang AE, Curran T, Provias J, Bergeron C. Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. Can J Neurol Sci 1994; 21:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massano J, Costa F, Nadais G. Teaching neuroImage: MRI in multiple system atrophy: "hot cross bun" sign and hyperintense rim bordering the putamina. Neurology 2008; 71:e38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muqit MM, Mort D, Miskiel KA, Shakir RA. "Hot cross bun" sign in a patient with parkinsonism secondary to presumed vasculitis. J Neurol Neurosurg Psychiatry 2001; 71:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bürk K, Skalej M, Dichgans J. Pontine MRI hyperintensities ("the cross sign") are not pathognomonic for multiple system atrophy (MSA). Mov Disord 2001; 16:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajaj S, Krismer F, Palma JA, et al. Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. PLoS One 2017; 12:e0189897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pellecchia MT, Barone P, Vicidomini C, et al. Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. Mov Disord 2011; 26:1303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marini C, Bandettini di Poggio M, Pomposelli E, et al. Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease and multiple system atrophy: implications for the diagnostic role of imaging. Clin Nucl Med 2010; 35:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagayama H, Ueda M, Yamazaki M, et al. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010; 25:1744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons C, Wang N, Rajan S, et al. Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease. Neurology 2023; 100:e1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donadio V, Incensi A, Rizzo G, et al. Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease With Orthostatic Hypotension. Mov Disord 2020; 35:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donadio V, Wang Z, Incensi A, et al. In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC. Neurology 2021; 96:e2513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Valbuena I, Visanji NP, Olszewska DA, et al. Combining Skin α-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease. Mov Disord 2022; 37:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellomo G, De Luca CMG, Paoletti FP, et al. α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward. Neurology 2022; 99:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes AJ, Colosimo C, Kleedorfer B, et al. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992; 55:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parati EA, Fetoni V, Geminiani GC, et al. Response to L-DOPA in multiple system atrophy. Clin Neuropharmacol 1993; 16:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albanese A, Colosimo C, Bentivoglio AR, et al. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry 1995; 59:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990; 113 ( Pt 6):1823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fetoni V, Genitrini S, Monza D, et al. Variations in axial, proximal, and distal motor response to L-dopa in multisystem atrophy and Parkinson's disease. Clin Neuropharmacol 1997; 20:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990; 13:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batla A, De Pablo-Fernandez E, Erro R, et al. Young-onset multiple system atrophy: Clinical and pathological features. Mov Disord 2018; 33:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002; 72:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinn N. Unilateral facial dystonia in multiple system atrophy. Mov Disord 1992; 7 Suppl 1:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Virameteekul S, Revesz T, Jaunmuktane Z, et al. Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord 2023; 38:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekiya H, Koga S, Murakami A, et al. Validation Study of the MDS Criteria for the Diagnosis of Multiple System Atrophy in the Mayo Clinic Brain Bank. Neurology 2023; 101:e2460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HJ, Jeon BS, Shin J, et al. Should genetic testing for SCAs be included in the diagnostic workup for MSA? Neurology 2014; 83:1733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 2015; 85:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miki Y, Foti SC, Asi YT, et al. Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain 2019; 142:2813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miki Y, Tsushima E, Foti SC, et al. Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy. Brain 2021; 144:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy MA, Friedman JH, Tetrud JW, Factor SA. Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases. J Clin Neurosci 2005; 12:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abele M, Bürk K, Schöls L, et al. The aetiology of sporadic adult-onset ataxia. Brain 2002; 125:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilman S, Little R, Johanns J, et al. Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology 2000; 55:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamelou M, Quinn NP, Bhatia KP. "Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide. Mov Disord 2013; 28:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mabuchi N, Hirayama M, Koike Y, et al. Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy. J Neurol Neurosurg Psychiatry 2005; 76:947.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4890 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19909915" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Multiple system atrophy: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20922810" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9040727" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Survival of patients with pathologically proven multiple system atrophy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23391524" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The natural history of multiple system atrophy: a prospective European cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25767079" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30789229" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043182" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32546656" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Predicting phenoconversion in pure autonomic failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28202694" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pure autonomic failure: Predictors of conversion to clinical CNS involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30135257" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The natural history of idiopathic autonomic failure: The IAF-BO cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28093795" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Natural history of pure autonomic failure: A United States prospective cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35445419" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10223419" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Consensus statement on the diagnosis of multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14747001" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7922469" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16092074" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : How to diagnose multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11960896" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18725592" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Second consensus statement on the diagnosis of multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24116345" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Tremor in Multiple System Atrophy - a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16049636" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The European Multiple System Atrophy-Study Group (EMSA-SG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32754107" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The Characteristics of Tremor Motion Help Identify Parkinson's Disease and Multiple System Atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1486465" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Stimulus-sensitive myoclonus in akinetic-rigid syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10634245" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Postural and action myoclonus in patients with parkinsonian type multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1557069" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7057212" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Olivopontocerebellar atrophy. A review of 117 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2564927" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Disproportionate antecollis in multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16703588" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Dropped head syndrome in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20014064" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Myopathy causing camptocormia in idiopathic Parkinson's disease: a multidisciplinary approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20108372" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Camptocormia in idiopathic Parkinson's disease: a focal myopathy of the paravertebral muscles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425791" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176961" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Parkinsonism and neck extensor myopathy: a new syndrome or coincidental findings?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11481704" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Focal myopathy as a cause of anterocollis in Parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27958390" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20683607" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15509623" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16511861" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31720822" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Early presentation of urinary retention in multiple system atrophy: can the disease begin in the sacral spinal cord?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22228725" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15300657" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9342156" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Value of sphincter electromyography in the diagnosis of multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8158782" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10918263" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Quantitative electromyography of the external anal sphincter in Parkinson's disease and multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29458746" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Stridor combined with other sleep breathing disorders in multiple system atrophy: a tailored treatment?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9109907" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : REM sleep behavior disorders in multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32234825" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Progression and prognosis in multiple system atrophy presenting with REM behavior disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20668263" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31570638" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27566741" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Early stridor onset and stridor treatment predict survival in 136 patients with MSA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21320989" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16093227" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20576697" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20535826" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34663646" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Fatigue in Patients With Multiple System Atrophy: A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15247536" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Olfaction and Parkinson's syndromes: its role in differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21840242" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Differentiating Parkinson's disease from multiple system atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19306362" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Proposed neuroimaging criteria for the diagnosis of multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7533048" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18838658" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Teaching neuroImage: MRI in multiple system atrophy: "hot cross bun" sign and hyperintense rim bordering the putamina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11601421" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : "Hot cross bun" sign in a patient with parkinsonism secondary to presumed vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11391754" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Pontine MRI hyperintensities ("the cross sign") are not pathognomonic for multiple system atrophy (MSA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29287113" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21469200" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20395701" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease and multiple system atrophy: implications for the diagnostic role of imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20645402" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36657992" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cutaneousα-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32557839" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease With Orthostatic Hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33837116" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35019153" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Combining Skinα-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35914941" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1469394" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The dopaminergic response in multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8477409" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Response to L-DOPA in multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7629528" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2276046" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Striatonigral degeneration. A clinicopathological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9197947" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Variations in axial, proximal, and distal motor response to L-dopa in multisystem atrophy and Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2276120" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Levodopa efficacy and pathological basis of Parkinson syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30153390" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Young-onset multiple system atrophy: Clinical and pathological features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11861684" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Dystonia in multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Unilateral facial dystonia in multiple system atrophy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36606594" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37816641" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Validation Study of the MDS Criteria for the Diagnosis of Multiple System Atrophy in the Mayo Clinic Brain Bank.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25298309" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Should genetic testing for SCAs be included in the diagnostic workup for MSA?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26138942" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31289815" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33822892" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16289932" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11960886" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The aetiology of sporadic adult-onset ataxia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10953186" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23720239" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : "Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15965200" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
